These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22424827)

  • 1. Release mechanism studies on TFu nanoparticles-in-microparticles system.
    Sun W; Zhang N; Li X
    Colloids Surf B Biointerfaces; 2012 Jun; 95():115-20. PubMed ID: 22424827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.
    Sun W; Zhang N; Li A; Zou W; Xu W
    Int J Pharm; 2008 Apr; 353(1-2):243-50. PubMed ID: 18155370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in Hâ‚‚â‚‚-bearing mice.
    Zhang J; Li M; Liu Z; Wang L; Liu Y; Zhang N
    Int J Nanomedicine; 2014; 9():2741-51. PubMed ID: 24920908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering effect of N-acetylglucosamine on retarded drug release from a lectin-anchored chitosan nanoparticles-in-microparticles system.
    Li H; Dong WF; Zhou JY; Xu XM; Li FQ
    Int J Pharm; 2013 Jun; 449(1-2):37-43. PubMed ID: 23587965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
    Zhang X; Zhong JL; Liu W; Gao Z; Xue X; Yue P; Wang L; Zhao C; Xu W; Qu X
    Cancer Chemother Pharmacol; 2010 May; 66(1):11-9. PubMed ID: 19756602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human gastric carcinoma cell growth by treatment of N(3)-o-toluyl-fluorouracil as a precursor of 5-fluorouracil.
    Liu J; Li X; Cheng YN; Cui SX; Chen MH; Xu WF; Tian ZG; Makuuchi M; Tang W; Qu XJ
    Eur J Pharmacol; 2007 Nov; 574(1):1-7. PubMed ID: 17904544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of nanoparticles-in-microparticles by a double emulsion method: a comprehensive study.
    Lee YS; Johnson PJ; Robbins PT; Bridson RH
    Eur J Pharm Biopharm; 2013 Feb; 83(2):168-73. PubMed ID: 23153669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid lipid nanoparticles prepared by solvent diffusion method in a nanoreactor system.
    Yuan H; Huang LF; Du YZ; Ying XY; You J; Hu FQ; Zeng S
    Colloids Surf B Biointerfaces; 2008 Feb; 61(2):132-7. PubMed ID: 17888636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation and investigation of 5-FU nanoparticles with factorial design-based studies.
    Bozkir A; Saka OM
    Farmaco; 2005 Oct; 60(10):840-6. PubMed ID: 16087183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting.
    Lai LF; Guo HX
    Int J Pharm; 2011 Feb; 404(1-2):317-23. PubMed ID: 21094232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cetirizine dihydrochloride loaded microparticles design using ionotropic cross-linked chitosan nanoparticles by spray-drying method.
    Li FQ; Ji RR; Chen X; You BM; Pan YH; Su JC
    Arch Pharm Res; 2010 Dec; 33(12):1967-73. PubMed ID: 21191762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation and passive target of 5-fluorouracil solid lipid nanoparticles.
    Du B; Yan Y; Li Y; Wang S; Zhang Z
    Pharm Dev Technol; 2010; 15(4):346-53. PubMed ID: 19769532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo studies of lipid-based nanocarriers for oral N3-o-toluyl-fluorouracil delivery.
    Liu C; Liu D; Bai F; Zhang J; Zhang N
    Drug Deliv; 2010 Jul; 17(5):352-63. PubMed ID: 20387993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) for cancer chemotherapy: preparation, characterization--in-vitro drug release and anti-tumour activity.
    Yan C; Chen D; Gu J; Qin J
    J Pharm Pharmacol; 2006 Sep; 58(9):1177-81. PubMed ID: 16945175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of nanoparticles-in-microparticles system for improved local retention after intra-articular injection.
    Chen Z; Liu D; Wang J; Wu L; Li W; Chen J; Cai BC; Cheng H
    Drug Deliv; 2014 Aug; 21(5):342-50. PubMed ID: 24215110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
    Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
    Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vitro anti-tumor efficacy and the pharmacokinetics of N3-o-toluyl-fluorouracil loaded nanosuspension (TFu-LNS).
    Li M; Zhang J; Feng L; Zhang L; Zhang N
    J Biomed Nanotechnol; 2013 May; 9(5):801-10. PubMed ID: 23802409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticles based on albumin: preparation, characterization and the use for 5-flurouracil delivery.
    Wilson B; Ambika TV; Patel RD; Jenita JL; Priyadarshini SR
    Int J Biol Macromol; 2012 Dec; 51(5):874-8. PubMed ID: 22820011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of nanosized niosomal dispersion for oral delivery of Ganciclovir.
    Akhter S; Kushwaha S; Warsi MH; Anwar M; Ahmad MZ; Ahmad I; Talegaonkar S; Khan ZI; Khar RK; Ahmad FJ
    Drug Dev Ind Pharm; 2012 Jan; 38(1):84-92. PubMed ID: 21726136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in-vitro and in-vivo study.
    Nagarwal RC; Singh PN; Kant S; Maiti P; Pandit JK
    Chem Pharm Bull (Tokyo); 2011; 59(2):272-8. PubMed ID: 21297311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.